Abstract
Traditionally, practitioners have reserved insulin therapy for patients with type 2 diabetes until diet, exercise, and treatment with oral agents have failed to maintain glycemic control. Increasing evidence, however, supports advancing insulin therapy earlier in treating diabetes, not only to normalize glycemic control and emulate normal physiologic insulin secretion, but also to delay or prevent disease-associated comorbidity.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Blood Glucose / metabolism*
-
Diabetes Mellitus, Type 2 / blood*
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Disease Progression
-
Drug Administration Schedule
-
Drug Monitoring / methods*
-
Drug Therapy, Combination
-
Humans
-
Insulin / pharmacokinetics
-
Insulin / therapeutic use*
-
Practice Guidelines as Topic
-
Sulfonylurea Compounds / therapeutic use
Substances
-
Blood Glucose
-
Insulin
-
Sulfonylurea Compounds